Modulating Movement Intention Via Cortical Stimulation
Recruiting · NCT03233399 · Interventional (participants receive a specific treatment) · Lead sponsor: NYU Langone Health
View the official record on ClinicalTrials.gov →Interventions studied
Anodal tDCS of left or right AG or FCSham TMS3 stimulationrTMS of left or right angular gyrus (AG) or frontal cortex (FC)
What this trial is about
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Healthy Controls)
- Fluent in English
- Patients with PMD or PNES):
- Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
- Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening
Exclusion criteria
- Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
- Chronic or progressive medical condition
- Any history of traumatic brain injury or significant head trauma
- Currently meets criteria for substance abuse or dependence
- History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
- Pregnancy
- Metal or devices in the head, including neurostimulators or metal foreign bodies
- Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
- Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
- Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
- Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
- PMD and PNES Patients
- Any history of traumatic brain injury or significant head trauma
- Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
- Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
- Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
- Metal or devices in the head, including neurostimulators or metal foreign bodies
- Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
- Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
- Recurrent visual hallucinations, within the past 6 months;
- History of significant uncontrollable movements of the head;
- Any clinically significant abnormality on vital signs
Where it is running
1 location listed across 1 US state.
- New York University School of Medicine - New York, New York, United States